/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Valued at a market cap of $82.9 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, manufactures, and commercializes medicines for treating various serious medical diseases. The Tarrytown, New York-based company’s portfolio boasts nine marketed drugs, which are Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap and is also known for developing an antibody cocktail for COVID-19, called REGEN-COV.
Companies valued at $10 billion or more are generally described as “large-cap” stocks, and Regeneron Pharmaceuticals fits right into that category. The biotech company is considered a pioneer in antibody research and is known for developing innovative medicines for patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases and various other rare diseases.